Bio: Alan Mertz is President of Mertz Strategies, LLC, and has more than 30 years of experience in government, leading health care trade associations, and advising laboratories on reimbursement and regulatory issues. He is currently a strategic government affairs consultant to NeoGenomics Laboratories, a premier cancer diagnostics and pharma services company. From 2003 to 2017, he was President of the American Clinical Laboratory Association (ACLA), where he led the clinical laboratory industry’s advocacy efforts on critical reimbursement and regulatory issues. During his tenure, ACLA’s membership, visibility, and advocacy effectiveness grew exponentially. Among ACLA’s advocacy successes during his tenure were stopping three proposals to impose coinsurance for laboratory services in Medicare, repealing a misguided Medicare ‘competitive bidding’ project, and defeating a new federal excise tax on all labortory reimbursement. In addition, Mertz led ACLA’s 13 year successful effort to hold off the FDA’s proposals to regulate Laboratory Developed Tests. Prior to joining ACLA, Mertz was Executive Vice President and Acting President of the Healthcare Leadership Council, and for 17 years served in three senior staff positions in the US House of Representatives and US Senate.